Pfizer agrees to new PET license, supply deal with cancer imaging firm ImaginAb
Pfizer and global immuno-cancer imaging agent provider ImaginAb have entered into a new positron emission tomography agent supply agreement, the pair announced Thursday.
Under the terms of the multi-year, non-exclusive license deal, Los Angeles-based ImaginAb will supply Pfizer with its 89Zr CD8 immuno-PET agent, which is used to image CD8 T cells in cancer patients.
“CD8 T cells play such a pivotal role in immunotherapy of many cancers and our 89Zr CD8 immuno-PET is one of the most widely used imaging technologies used by pharmaceutical and biotech companies to track CD8 T cells in patients,” Ian Wilson, CEO of ImaginAB, said in a statement.
ImaginAb will supply Pfizer with clinical doses of the molecular imaging agent for the latter to use in oncology trials. ImaginAb will also offer its technical, clinical and regulatory support and receive license fees and payments for manufacturing and other needs, according to the announcement.
No other terms of the deal were disclosed.
“Our goal is to enable the widespread use and adoption of 89Zr CD8 immuno-PET technology, which will help our partners to predict therapeutic efficacy and treatment outcomes in cancer patients more precisely and earlier in a clinical trial,” Wilson added Thursday. “Working with leading pharmaceutical companies such as Pfizer, will help us achieve our goal."
Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.